Sporadic MTC (sMTC) constitutes approximately 75% of cases, with the prominent driver pathways identified as mutually exclusive mutations in the RET proto-oncogene and RAS [3-5]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.